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The prognosis of adult soft tissue sarcoma (STS) patients with metastases is generally poor. As little is known about the impact of
the involvement of different metastatic sites and the extent of pulmonary lesions on the outcome for patients receiving first-line
chemotherapy, we aimed to establish prognostic factors for STS patients with lung metastases only. A retrospective, exploratory
analysis was performed on 2,913 metastatic STS patients who received first-line chemotherapy. Detailed information from 580
patients who had lung metastases only, was used for prognostic factor analysis. Patients with lung metastases only were more
often asymptomatic and had undergone complete primary tumor resection more frequently compared to patients with additional
metastases outside the lung or without lung metastases. For extremity STS, the incidence of lung metastases only was much
higher compared to non-extremity STS. Lung involvement only was an independent favorable prognostic factor for overall survival
(OS) with regard to metastatic site. Within this subgroup, in a multivariate model, other factors associated with improved OS
included: good performance status (PS), no progression at primary site, low histological grade, younger age, long interval between
initial diagnosis and trial registration, and smaller diameter of the largest lung lesion. This unique analysis on prognostic factors in
STS patients with lung metastases confirms well-known patient factors (such as age and PS), and tumor characteristics (including
tumor grade, interval between primary diagnosis, and metastases), but also identifies diameter of the largest lung lesion as a new
prognostic factor. Knowledge about these factors may support decision-making within multidisciplinary tumor boards.
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Highlights
• We established prognostic factors for soft tissue sarcoma
patients with lung metastases only on the largest dataset
of 580 patients.
• The largest diameter of a lung lesion has been proven
among others for the ﬁrst time to serve as a new prog-
nostic factor.
• Knowledge about these factors may support decision-
making within multidisciplinary tumor boards.
Introduction
Soft tissue and visceral sarcomas represent a rare group of
mesenchymal tumors with greater than 70 different subtypes.
The incidence in Europe and the United States is less than 5
per 100.000 per year.1,2 They occur at various anatomic
sites with extremities (43%), trunk (10%), visceral (19%), ret-
roperitoneum (15%), and head and neck (9%) as the most
common primary sites.3 The three stage grading system
established by the French sarcoma group (FNCLCC) discrim-
inates rarely metastasizing grade 1 tumors from grade 2 and
3 tumors with high metastatic potential. Other important
characteristics leading to an increased risk of metastasis for-
mation are size and depth of the primary tumor.4 Most soft
tissue sarcoma (STS) metastasize hematogenously with the
lung as main target organ.5 Exceptions are synovial sarcoma,
clear cell sarcoma, rhabdomyosarcoma, and epithelioid sar-
coma, which also spread via the lymphatic system.6
Based on previous analyses, approximately 20–25% of all
STS patients will develop pulmonary metastases (40–60% for
high grade tumors), which will become clinically evident usu-
ally in the ﬁrst 2 years following diagnosis.7 For extremity
STS, radiotherapy in addition to surgical removal of the
tumor has been shown to reduce the risk of local recurrence
but it has no impact on survival.8,9 Systemic spread seems to
be an early event in STS. Amputation of extremity tumors
compared to limb sparing procedures did not result in
improved survival rates.10 Surgical resection of metachronous
lung metastases is always considered in the case of limited
disease and longer interval since primary surgery as it has
been associated with long-term survival.11,12
Prognostic factors associated with improved survival after
pulmonary metastasectomy are based on a variety of surgical
series. Factors associated with improved survival are a lim-
ited number of metastases (3), long disease-free interval
(>12 months), and the ability to completely resect the pul-
monary lesions.13,14 In contrast, it was recently shown that
progression on preoperative chemotherapy before pulmo-
nary metastasectomy was an independent negative prognos-
tic factor for survival.15
In metastatic patients not amenable to surgery, palliative
chemotherapy is the treatment of choice. Median overall sur-
vival for these patients is about 12 months, but appears to be
rising in certain subtypes such as leiomyosarcomas with the
arrival of new agents.16 Doxorubicin is the most active drug
for metastatic STS and remains the standard ﬁrst-line therapy
for these patients. The most recent randomized phase III
trial comparing doxorubicin with doxorubicin plus ifosfa-
mide did not show an overall survival beneﬁt for the com-
bination therapy.17 Furthermore, the approved second-line
agent trabectedin did not improve progression free survival
and had more toxicity compared to doxorubicin, and simi-
lar results were observed comparing the combination of
gemcitabine and docetaxel with doxorubicin in the ﬁrst-
line therapy.18,19
Recently, olaratumab, an anti-PDGFRa monoclonal anti-
body, received conditional approval based on overall survival
beneﬁt in combination with doxorubicin over doxorubicin
alone based on data from a randomized phase II study.
Results of the phase 3 study are awaited with great
interest.20
The aim of the present retrospective exploratory analysis,
on data from the EORTC database on 2,913 metastatic STS
patients who received ﬁrst-line chemotherapy, was to identify
prognostic and predictive factors for overall survival (OS)
and progression-free survival (PFS) of 580 patients with lung
metastases only.
Patients and Methods
Patients
In total, 3,708 patients were treated in ﬁfteen EORTC
advanced soft tissue sarcomas trials. We excluded patients
without metastases who received prior adjuvant or palliative
chemotherapy and who were diagnosed with a gastrointesti-
nal stromal tumor (GIST), limiting the current analysis to
2,913 patients. For the prognostic factor analysis, 1,078
patients with lung metastases only were selected. Detailed
information on lung metastases (such as the number and
diameter of lesions) had been collected in 10 of the 15 ﬁrst-
line studies (62,883, 62,901, 62,903, 62,912, 62,941, 62,953,
62,971, 62,012, 62,061, and 62,091), which ﬁnally led to
data of 580 patients that qualiﬁed for the prognostic factor
analysis.
What’s new?
About 25% of soft tissue sarcoma patients develop lung metastases but prognostic factors for those who cannot get operated
remain scarce. Here the authors performed a retrospective study of datasets obtained from 580 patients where metastases
have not spread beyond the lung and who received first-line chemotherapy but no resection. Interestingly, the largest diame-
ter of a lung lesion emerged as a new prognostic factor, a finding, which may influence clinical decisions in the future.
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End-points
The end points of this analysis were PFS and OS. PFS is
deﬁned as the time interval between the date of randomiza-
tion or the date of prospective registration in the non-
randomized trials and the date of ﬁrst report of progression
or death, whichever comes ﬁrst. The patients who are alive
and without progressive disease at the last follow up date are
censored. Likewise, OS is computed from the date of ran-
domization in the randomized trials or the date of prospec-
tive registration in the nonrandomized trials until the date of
death. Patients who are alive at the last follow up date are
censored.
Explored covariates
The variables included in the study were the demographic
data, the previous history of the sarcoma, the treatment, and
the histology. For the prognostic factor analysis, the charac-
teristics of the pulmonary lesions in particular the diameter
of the largest lesions and the total number of lesions were
investigated. The demographic variables included age (by 10
years), sex, and performance status before the start of chemo-
therapy. Performance status (PS) was measured on the WHO
scale (except for two trials in which it was retrospectively
converted from Karnofsky scale to the WHO scale). As few
patients had a level 3 PS, the level 2 and 3 were combined in
the same category named “PS 21.” Variables related to the
history of sarcoma included prior radiotherapy as well as the
time since the ﬁrst diagnosis of sarcoma (in years). Prior che-
motherapy was an exclusion criterion. For the histological
diagnosis and the grade, we used the centrally reviewed diag-
nosis when available (around 60%), otherwise the local diag-
nosis was used. Histological subtypes were aggregated into
the four most common groups: leiomyosarcoma, synovial sar-
coma, liposarcoma, and others. The treatment was aggregated
in the four categories: anthracyclines alone (doxorubicin 1 *
75 mg/m2, caelyx 1 * 50 mg/m
2, epirubicin 1 * 75 mg/m
2,
epirubicin 3 * 50 mg/m
2, epirubicin 1 * 150 mg/m
2), ifosfa-
mide alone (ifosfamide 5 g/m2/24 hr continuous infusion,
ifosfamide 3 * 3 g/m
2, ifosfamide 9 g/m2/72 hr continuous
infusion, ifosfamide 12 g/m2/72 hr continuous infusion), the
combination of doxorubicin and ifosfamide (doxorubicin
50 mg/m21 ifosfamide 5 g/m2/24 hr continuous infusion,
doxorubicin 75 mg/m21 ifosfamide 5 g/m2/24 hr continuous
infusion), CYVADIC (cyclophosphamide 500 mg/m2, vincris-
tine 1.5 mg/m2, doxorubicin 50 mg/m2, dacarbazine 750 mg/
m2), and other (brostallicin 10 mg/m2, trabectedin 1.5 mg/
m2/24 hr or 1.3 mg/m2/3 hr) (Supporting Information
Appendix Table 1). This variable was used as a stratiﬁcation
factor in the univariate analyses.
Statistical methods
All baseline variables were described. The categorical data
were summarized by the frequencies and percentages, and
the continuous covariates were summarized with median,
range and numbers of non-missing observations. The statisti-
cal test used for comparison was a v2 (or a ﬁsher) test for
categorical covariates. A Kruskall–Wallis test was used for
covariates with more than two ordered categories or for con-
tinuous variables. Median follow-up was calculated from
reverse Kaplan–Meier estimates. PFS and OS were estimated
using the Kaplan–Meier estimate and compared between sub-
groups of metastatic involvement using a Cox proportional
hazards models stratiﬁed by treatment and study to try to
account for potential heterogeneity among the trials. The
potential prognostic value of all factors was ﬁrst investigated
by univariate analyses, using a univariate Cox model stratiﬁed
by treatment. The overall and progression free survival curves
were presented for factors that were signiﬁcant. Factors
included in the multivariate model (also stratiﬁed by treat-
ment) were identiﬁed by a backward selection procedure
which included all the covariates in the model and removed,
one at a time, those whose p values was higher than 0.05.
Multivariate analysis required complete information for all
patients on all covariates included in the model. To protect
against a considerable loss of information for the multivariate
analysis in case of substantial missing data in one or more of
the covariates, we considered for some covariates the
“missing” as a separate category in these models (prior sur-
gery, primary site involved, site of primary and grade). The
statistical signiﬁcance was set at 0.05 for all the analyses in
this report.
Results
Baseline characteristics of all 2,913 metastatic STS patients
were categorized according to the site of metastatic involve-
ment “lung lesions only,” “other lesions only,” and “both
type of lesions” (Table 1). In the univariate analysis, the
patients’ characteristics differed across the populations for
treatment, gender, PS, age, time between initial diagnosis,
and registration, prior surgery, prior radiotherapy, histology,
histopathological grade, site of primary tumor, and whether
the primary site was involved.
There were slightly more male patients with lung lesions
only, whereas more female patients had metastatic sites
including lung and other lesions. This was probably related
to the gynecologic sarcomas (N5 308) which were associated
in 62% of patients with lesions also outside the lungs (Sup-
porting Information Appendix Table 3). A PS of 0 was
observed more frequently in the “only lung metastases” group
as compared to the other two groups. The median age in the
three groups was comparable. The interval between initial
diagnosis and registration was the longest for patients with
lung metastases only. The majority of patients had a prior
surgery of their primary tumor which was more often a com-
plete resection for patients with lung metastasis as compared
to the others. About 10% of the patients had synovial sar-
coma and liposarcoma (9.6 and 9.1%, respectively), 31.6%
had leiomyosarcoma, but the majority had another type of
sarcoma (46.4%). Remarkably, synovial sarcoma metastases
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Table 1. Characteristics of 2,913 metastatic sarcoma patients receiving first-line chemotherapy\
Lesions
Total
(N52,913)
Lung lesions only
(N51,078)
Other lesions only
(N5936)
Both
(N5899)
p-valueN (%) N (%) N (%) N (%)
Treatment <0.0011
Anthracyclines 383 (35.5) 388 (41.5) 347 (38.6) 1118 (38.4)
DOX1 IFO 354 (32.8) 300 (32.1) 294 (32.7) 948 (32.5)
CYVADIC 157 (14.6) 109 (11.6) 89 (9.9) 355 (12.2)
Ifo ALONE 138 (12.8) 99 (10.6) 98 (10.9) 335 (11.5)
Other 46 (4.3) 40 (4.3) 71 (7.9) 157 (5.4)
Gender 0.0071
Male 576 (53.4) 470 (50.2) 416 (46.3) 1462 (50.2)
Female 502 (46.6) 466 (49.8) 483 (53.7) 1451 (49.8)
Performance status <0.0011
PS 0 548 (50.8) 394 (42.1) 353 (39.3) 1295 (44.5)
PS 1 445 (41.3) 453 (48.4) 450 (50.1) 1348 (46.3)
PS 21 71 (6.6) 79 (8.4) 84 (9.3) 234 (8.0)
Missing 14 (1.3) 10 (1.1) 12 (1.3) 36 (1.2)
Age
40 years 292 (27.1) 187 (20.0) 192 (21.4) 671 (23.0)
40–50 years 231 (21.4) 200 (21.4) 225 (25.0) 656 (22.5)
50–60 years 303 (28.1) 291 (31.1) 268 (29.8) 862 (29.6)
>60 years 234 (21.7) 252 (26.9) 204 (22.7) 690 (23.7)
Missing 18 (1.7) 6 (0.6) 10 (1.1) 34 (1.2)
Median 50 52 51 52 <0.0012
Range 16–88 10–80 17–84 10–88
Q1–Q3 39–59 43–61 42–60 41–60
Time between initial diagnosis
and registration
6 months 456 (42.3) 488 (52.1) 436 (48.5) 1380 (47.4)
6–12 months 159 (14.7) 91 (9.7) 100 (11.1) 350 (12.0)
1–2 years 195 (18.1) 102 (10.9) 123 (13.7) 420 (14.4)
>2years 224 (20.8) 192 (20.5) 193 (21.5) 609 (20.9)
Missing 44 (4.1) 63 (6.7) 47 (5.2) 154 (5.3)
Median (months) 9 6 7 7 0.0012
Range (months) 0–312 0–347 0–250 0–347
Q1–Q3 (months) 2–21 1–21 2–22 2–21
Prior surgery <0.0011
No surgery 90 (8.3) 91 (9.7) 64 (7.1) 245 (8.4)
Non-optimal surgery 136 (12.6) 145 (15.5) 88 (9.8) 369 (12.7)
Complete surgery 437 (40.5) 187 (20.0) 206 (22.9) 830 (28.5)
Other/Unknown 415 (38.5) 513 (54.8) 541 (60.2) 1469 (50.4)
Prior radiotherapy <0.0011
No 595 (55.2) 732 (78.2) 511 (56.8) 1838 (63.1)
Yes 416 (38.6) 143 (15.3) 286 (31.8) 845 (29.0)
Missing 67 (6.2) 61 (6.5) 102 (11.3) 230 (7.9)
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almost always affected the lungs with only 10% of patients
having lesions solely outside the lungs, whereas liposarcoma
metastases were mainly located outside the lungs (51.1%
other lesions only and 23.5% both types of lesions). The next
histologic subtype associated with a high prevalence of metas-
tases sparing the lungs was leiomyosarcoma, with 41.1% of
patients showing metastases only outside the lungs. The
group of other STS was a mixed group of histologies, whereas
nowadays the diagnosis can be better deﬁned than in the ear-
lier studies. Thirty percent of grading data were missing,
almost half of the STS had grade 3 and 11% had grade 1.
Patients with metastatic lesions only outside the lungs had
twice as often a grade I tumor as compared to the other two
groups. Information about the localization of the primary
tumor was incompletely reported but the majority were non-
extremity STS. These patients developed metastases outside
the lungs more frequently as compared to the extremity
Group (41.2 vs. 15.6%, respectively) (Table 1).
At the time of the respective study clinical data cut-offs,
18.5% of patients were still alive with a median follow-up
time of 16 months. These patients were considered as cen-
sored for OS and PFS analysis. In terms of OS patients with
lung metastases only had a better prognosis than patients
with other metastases only (stratiﬁed HR5 1.14; 95% CI,
1.03–1.26) or patients with both types of metastases (strati-
ﬁed HR5 1.24; 95% CI, 1.16–1.43). This was also the case
for PFS where patients with lung metastases only had a lon-
ger PFS as compared to the group with other lesions only
Table 1. Characteristics of 2,913 metastatic sarcoma patients receiving first-line chemotherapy\ (Continued)
Lesions
Total
(N52,913)
Lung lesions only
(N51,078)
Other lesions only
(N5936)
Both
(N5899)
p-valueN (%) N (%) N (%) N (%)
Histology <0.0011
Leiomyosarcoma 261 (24.2) 378 (40.4) 281 (31.3) 920 (31.6)
Synovial sarcoma 176 (16.3) 29 (3.1) 75 (8.3) 280 (9.6)
Liposarcoma 67 (6.2) 135 (14.4) 62 (6.9) 264 (9.1)
Other 539 (50.0) 353 (37.7) 459 (51.1) 1351 (46.4)
Missing 35 (3.2) 41 (4.4) 22 (2.4) 98 (3.4)
Histopathological grade <0.0011
Grade 1 65 (6.0) 115 (12.3) 54 (6.0) 234 (8.0)
Grade 2 261 (24.2) 266 (28.4) 267 (29.7) 794 (27.3)
Grade 3 412 (38.2) 275 (29.4) 325 (36.2) 1012 (34.7)
Missing 340 (31.5) 280 (29.9) 253 (28.1) 873 (30.0)
Site of primary tumor <0.0011
Other than extremity 349 (32.4) 520 (55.6) 393 (43.7) 1262 (43.3)
Extremity 416 (38.6) 131 (14.0) 294 (32.7) 841 (28.9)
Missing 313 (29.0) 285 (30.4) 212 (23.6) 810 (27.8)
Primary site involved <0.0011
No 619 (57.4) 329 (35.1) 436 (48.5) 1384 (47.5)
Yes 366 (34.0) 400 (42.7) 333 (37.0) 1099 (37.7)
Missing 93 (8.6) 207 (22.1) 130 (14.5) 430 (14.8)
Involved sites
Lung lesions only 1078 (100.0) 0 (0.0) 0 (0.0) 1078 (37.0)
Liver lesions 0 (0.0) 195 (20.8) 86 (9.6) 281 (9.6)
Bone lesions 0 (0.0) 43 (4.6) 107 (11.9) 150 (5.1)
Other lesions 0 (0.0) 491 (52.5) 481 (53.5) 972 (33.4)
Liver and bone lesions 0 (0.0) 8 (0.9) 31 (3.4) 39 (1.3)
Liver and other lesions 0 (0.0) 147 (15.7) 75 (8.3) 222 (7.6)
Bone and other lesions 0 (0.0) 34 (3.6) 85 (9.5) 119 (4.1)
Liver, bone, and other lesions 0 (0.0) 18 (1.9) 34 (3.8) 52 (1.8)
1v2.
2Kruskall–Wallis.
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(stratiﬁed HR5 1.20; 95% CI, 1.09–1.31) or the group with
both type of lesions (stratiﬁed HR5 1.31; 95% CI, 1.19–1.44)
(Fig. 1).
Prognostic factors for OS in patients with measured lung
metastases only
In univariate analysis, PS, histopathological grade, time
between the initial diagnosis and registration, and the diame-
ter of the largest lung lesion were all signiﬁcant prognostic
factors at the level of 0.05. Choice of chemotherapy regimen
had signiﬁcant impact on OS with a better outcome for
doxorubicin plus ifosfamide as compared to doxorubicin
alone (Supporting Information Appendix Table 4). Multivari-
ate analysis was performed on a subset of 504 patients with
all necessary information available. Performance status was a
very strong prognostic factor together with histopathological
grade, involvement of primary site, time between the diagno-
sis and registration, and the diameter of the largest lung
lesion (Table 2). We also performed the multivariate analysis
adjusting for treatment as a covariate but stratifying by study
to account for between study heterogeneity. This resulted in
the same ﬁnal model, with similar HR estimates (data not
shown).
Prognostic factor for PFS in patients with measured lung
metastases only
In univariate analysis, treatment, PS, number of lung lesions,
interval between initial diagnosis and registration, and size of
the largest pulmonary lesion were signiﬁcant (Supporting
Information Appendix Table 5). Median PFS was highest for
patients treated with doxorubicin plus ifosfamide followed by
anthracycline monotherapy, ifosfamide and trabectedin or
brostallicin. In the multivariate analysis, stratiﬁed by treat-
ment, on a subset of 504 patients where all covariates were
available, PS, time between the diagnosis and registration and
the diameter of the largest lung lesions were found to be sig-
niﬁcant prognostic factors for PFS (Table 3). The sensitivity
analysis adjusting for treatment as a covariate, but stratifying
by study, resulted in the same ﬁnal model, with similar HR
estimates (data not shown).
Discussion
In this unique and largest series of 580 patients with lung
metastases not amenable to surgery and treated with ﬁrst-line
chemotherapy in EORTC STBSG trials over 30 years, we
aimed to ﬁnd prognostic factors for OS and PFS. So far, out-
come of patients with lung metastases only was reported
mainly from surgical series. Casson et al. in 1992, reported
about 58 patients with pulmonary metastases of STS who
underwent complete resection of pulmonary metastases. They
identiﬁed as independent prognostic factors for improved OS:
metastasis doubling time of 40 days or greater, unilateral dis-
ease on preoperative radiography, three or fewer nodules on
preoperative computed tomography, two or less nodules
resected, and tumor histology (malignant ﬁbrous histiocy-
toma better than others). Multivariate analysis identiﬁed the
number of nodules detected by computed tomography preop-
eratively as having signiﬁcant prognostic value.21 Later, in
1999, Billingsley et al. reported about 719 patients with lung
metastases as a single institution experience of the Memorial
Sloan-Kettering Cancer Center. One third of the patients
underwent metastasectomy and complete surgical resection of
all lung metastasis had the greatest impact on survival. On
univariate analysis, patient age 50 years or older and high-
grade tumors were predictors of negative outcome. Again,
patients with 4 number of lung lesions or unilateral disease
had a slightly more favorable survival although this was not
statistically signiﬁcant. For multivariate analysis, surgical
resection remained the most signiﬁcant predictor of post-
metastases survival followed by a disease-free interval of
greater than 12 months and low grade histology of the pri-
mary tumor. Predictors of poor outcome were liposarcoma
and malignant peripheral nerve sheet tumor histology, and
age 50 years.13
Figure 1. Overall survival (a) and progression free survival (b) of 2,913 metastatic sarcoma patients receiving first-line chemotherapy with
lung lesions only, other lesions only, or both types of lesions. [Color figure can be viewed at wileyonlinelibrary.com]
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In line with the surgical series, histopathological grade, age
and time between initial diagnosis and treatment have been
proven to serve as prognostic factors also for the non-surgically
treated patients. The factors PS and involvement of primary site
were described for the ﬁrst time as prognostic in patients with
lung metastases only who were treated with ﬁrst-line chemo-
therapy. Whereas the number of metastases or unilaterality were
prognostic in the surgical series, the size of the largest lung
lesion was prognostic for OS and PFS within this analysis. How-
ever, this might be biased by the different way of reporting for
chemotherapy trials where tumor load is deﬁned by RECIST cri-
teria, taking into account only measurable lesions (10 mm).22
STS affects men and women with equal frequency which was
also true for this analysis.23 However, men were more frequently
recorded with lung lesions only as compared to women where
lung lesions were more often associated with other metastatic
Table 2. Multivariate analysis, stratified by treatment, of 580 patients (504 with complete covariate information) with lung metastases only
for overall survival
Parameter Levels
Hazard ratio
(95% CI) p-value
Performance status PS 0 1.00 <0.001 (df52)
PS 1 1.72 (1.39, 2.13)
PS 21 5.17 (2.64, 10.1)
Primary site involved No 1.00 0.030 (df52)
Yes 1.39 (1.08, 1.77)
Missing 1.26 (0.89, 1.80)
Histopathological grade Grade I 1.00 0.011 (df53)
Grade II 1.27 (0.84, 1.90)
Grade III 1.72 (1.16, 2.57)
Missing 1.39 (0.89, 2.16)
Time between initial diagnosis 6 months 1.00 <0.001 (df53)
1–2 years 1.06 (0.79, 1.41)
6–12 months 1.18 (0.87, 1.61)
>2 years 0.57 (0.43, 0.75)
Size of largest lung lesion <20 mm 1.00 <0.001 (df54)
20–30 mm 1.23 (0.92, 1.65)
30–40 mm 2.17 (1.53, 3.08)
40–50 mm 1.30 (0.90, 1.89)
50 mm 2.05 (1.54, 2.73)
Table 3. Multivariate analysis, stratified by treatment, of 580 patients (504 with complete covariate information) with lung metastases only
for progression free survival
Parameter Levels
Hazard ratio
(95% CI) p-value
Performance status PS 0 1.00 <0.001 (df52)
PS 1 1.29 (1.06, 1.56)
PS 21 3.44 (1.80, 6.55)
Time between initial diagnosis 6 months 1.00 <0.001 (df53)
1–2 years 0.93 (0.72, 1.20)
6–12 months 1.21 (0.92, 1.58)
>2 years 0.64 (0.50, 0.81)
Size of largest lung lesion <20 mm 1.00 0.024 (df54)
20–30 mm 1.30 (1.00, 1.69)
30–40 mm 1.55 (1.14, 2.12)
40–50 mm 1.46 (1.06, 2.03)
50 mm 1.38 (1.07, 1.79)
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lesions. This is probably related to the gynecologic sarcomas
which in a majority of women develop metastases also outside
the lungs. Patients with lung lesions only are usually less symp-
tomatic than patients with lesions in liver, bone, or other parts
of the body. This lead to an imbalance between the three
cohorts with more PS0 patients in the lung only group. This
may also explain why for patients with lung metastasis only the
delay between initial diagnosis and registration was the longest.
Interestingly, the patients of the cohort with lung lesions
only were younger as compared to the others. Whether this
is related to different histologies in the three age groups
(40 years, 40–50 years, and 50–60 years) cannot be clariﬁed
as up to 50% of the histologies were grouped as “other” due
to the difﬁculty in veriﬁcation of histological subtypes over
the different study generations, not allowing for further dis-
crimination. However, as only 60% of all cases were analyzed
Figure 2. Overall survival in 580 sarcoma patients with lung metastases only by type of chemotherapy treatment (a), performance status
(b), histopathological grading (c), time between the initial diagnosis and start of treatment (d), and by diameter of the largest lung lesion (e).
[Color figure can be viewed at wileyonlinelibrary.com]
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by a review pathologist, the precision of the histologic analy-
sis remains questionable and cannot be compared to more
recent studies. We, therefore, also did an analysis on patients
where histology was reviewed, but this did not change the
conclusions (results not shown).
Extremity STS patients have a higher chance to have
achieved complete tumor resection as compared to retroperito-
neal or intraperitoneal localizations but they also have a higher
risk for pulmonary metastatic disease.24 This is in line with the
ﬁnding that STS patients who had prior complete surgery were
more frequently diagnosed with pulmonary lesions only. Radio-
therapy was mainly administered in case of extremity STS and
was therefore also more often represented in the lung metastases
only group. Leiomyosarcoma and “other” STS were the main
tumor histologies. Regarding the incidence of sarcoma subtypes
especially in metastatic patients undifferentiated pleomorphic
sarcoma (UPS) have to be assumed as another large subgroup
and aggressive uterine sarcomas in the female population, likely
Figure 3. Progression free survival in 580 sarcoma patients with lung lesions only by type of chemotherapy treatment (a), performance status
(b), number of lung lesions (c), diameter of the largest lung lesion (d), and time between the initial diagnosis and start of treatment (e). [Color
figure can be viewed at wileyonlinelibrary.com]
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responsible for the higher proportion of lesions outside the lungs
in women. The proportion of grade I tumors was below 10% for
all patients but signiﬁcantly higher for patients with metastases
outside the lungs. This reﬂects the low metastatic potential for
low grade tumors but may indicate the higher proportion of
non-extremity grade 1 tumors, for example, well-differentiated
liposarcoma in this patient cohort. Patients with lung lesions
only originate mainly from extremity primary tumors, which
are easier to be completely resected as is the case for other local-
izations. Therefore, for patients with lung lesions only the pri-
mary tumor is more often controlled. This could also explain
the better outcome of the lung metastases only group with sig-
niﬁcantly improved OS and PFS as compared to the other two
groups (Figs. 1a and 1b). As the site of tumor metastasis is
dependent on the tumor subtype (see Table 1), this result may
also reﬂect the prognosis of the different tumor subtypes with
recently describe leiomyosarcoma patients doing better than lip-
osarcoma or undifferentiated pleiomorphic sarcoma.25 The
involvement of the liver in about 20% of patients and bone in
about 10% of patients with metastases outside the lungs is in
line with other reports of metastatic STS patients.26,27
PS scores are widely used in oncological practice because
they correlate with patient survival duration and response to
treatment and have proven to serve as independent prognostic
factors despite the development of many biomarkers in most
cancers.28,29 Age did prove as prognostic factor in multivariate
analysis but we only have a limited number of about 10% of
patients older than 65 years in the EORTC data base treated
with ﬁrst-line chemotherapy in STS.30,31 A longer interval
between diagnosis and registration for chemotherapeutic treat-
ment for metastatic disease reﬂects the clinical course of the
disease and is most likely related to lower tumor grade. Histo-
logical grade was prognostic for OS but not for PFS reﬂecting
that high grade tumors are more likely to respond to chemo-
therapy but have also a higher risk to progress thereafter.28
With regard to the characteristics of the lung metastases size of
the largest lesion was prognostic for OS and PFS. Of note,
detection of non-target lesions in the lungs was associated with
the worst outcome. Most likely these patients had pleural
involvement which is associated with higher morbidity, com-
pared to intrapulmonary lesions.29 Median OS and PFS of
patients with pulmonary metastases only was highest for
patients treated with doxorubicin plus ifosfamide followed by
anthracycline monotherapy, ifosfamide and trabectedin or
brostallicin. In the multivariate analysis there was a 31% risk
reduction for the combination therapy compared to anthracy-
cline monotherapy with regard to PFS (HR5 0.69, p< 0.001).
These results are in line with the most recent phase III trial
comparing doxorubicin monotherapy with the combination of
doxorubicin and ifosfamide (Fig. 2 and 3).17
This analysis is restricted by the fact that data encompass-
ing greater than 25 years of sarcoma research were pooled to
increase the patient number and clinical signiﬁcance of the
study. With the introduction of modern imaging technology
and new treatment options that are more tumor histology
driven, prognosis of patients may change in due course. This
may also have an impact for analyses such as the current
one. Therefore, a stratiﬁed approach (by treatment and/or
study when feasible in terms of sample size and events in the
proposed strata) was adopted. Interestingly, stratiﬁcation had
only a minimal impact on the estimates obtained from the
different models when compared to unstratiﬁed analyses, sug-
gesting limited presence of heterogeneity. Another limitation
of the retrospective nature of our study is the amount of
missing data in potentially important prognostic factors such
as prior surgery, primary site involved, site of primary, and
grade. Treating the missing information as a separate cate-
gory was a pragmatic solution to avoid the loss of a substan-
tial subgroup of patients in a complete case analysis. Multiple
imputation of the missing data was not considered feasible in
this analysis, as the proportion of missing data was quite
large, and was sometimes of a structural nature (i.e., not
being collected as part of the clinical study data).
Despite these limitations, with the largest data set ever
investigating the role of localization of metastases in soft tis-
sues sarcoma patients amenable to ﬁrst-line chemotherapy,
we conﬁrmed general known prognostic factors for OS and
PFS but added more detailed information regarding the
impact of the status of the primary tumor and the size of the
largest pulmonary metastasis.
With this extended report, we aimed to provide signiﬁcant
information on prognostic factors which may help to take
optimal decisions in multidisciplinary sarcoma meetings and
guide shared decision making with patients confronted with
metastases of soft tissue sarcomas.
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